期刊
CELL REPORTS
卷 26, 期 8, 页码 2166-+出版社
CELL PRESS
DOI: 10.1016/j.celrep.2019.01.082
关键词
-
类别
资金
- NSFC, China [81770438, 91439122, 81473138]
- National Key Research and Development Program of China [2017YFA0505100]
- Major Research Program of Guangdong Science Technology [2017A030308002, 2015B010109004]
- Academy of Finland [285223]
- Sigrid Juselius Foundation
- Magnus Ehrnrooth Foundation
- Finnish Foundation for Cardiovascular Research
Leukemia stem cells (LSCs) are a rare subpopulation of abnormal hematopoietic stem cells (HSCs) that propagates leukemia and are responsible for the high frequency of relapse in therapies. Detailed insights into LSCs' survival will facilitate the identification of targets for therapeutic approaches. Here, we develop an inhibitor, LYZ-81, which targets ORP4L with high affinity and specificity and selectively eradicates LCSs in vitro and in vivo. ORP4L is expressed in LSCs but not in normal HSCs and is essential for LSC bioenergetics and survival. It extracts PIP2 from the plasma membrane and presents it to PLC beta 3, enabling IP3 generation and subsequentCa(2+)-dependent bioenergetics. LYZ-81 binds ORP4L competitively with PIP2 and blocks PIP2 hydrolysis, resulting in defective Ca2+ signaling. The results provide evidence that LSCs can be eradicated through the inhibition of ORP4L by LYZ-81, which may serve as a starting point of drug development for the elimination of LSCs to eventually cure leukemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据